HUP0001063A2 - Zöld porfirinek alkalmazása ateroszklerózis kezelésére szolgáló gyógyászati készítmények előállítására - Google Patents

Zöld porfirinek alkalmazása ateroszklerózis kezelésére szolgáló gyógyászati készítmények előállítására

Info

Publication number
HUP0001063A2
HUP0001063A2 HU0001063A HUP0001063A HUP0001063A2 HU P0001063 A2 HUP0001063 A2 HU P0001063A2 HU 0001063 A HU0001063 A HU 0001063A HU P0001063 A HUP0001063 A HU P0001063A HU P0001063 A2 HUP0001063 A2 HU P0001063A2
Authority
HU
Hungary
Prior art keywords
manufacture
green
inhibiting
development
preventing
Prior art date
Application number
HU0001063A
Other languages
English (en)
Inventor
Barbara Kelly
Julia Levy
Philippe Maria Clotaire Margaron
Original Assignee
Qlt Phototherapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qlt Phototherapeutics, Inc. filed Critical Qlt Phototherapeutics, Inc.
Publication of HUP0001063A2 publication Critical patent/HUP0001063A2/hu
Publication of HUP0001063A3 publication Critical patent/HUP0001063A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány tárgyát érlerakódás kifejlődésének gátlására vagymegelőzésére alkalmas gyógyászati készítmény és ennek alkalmazásaképezi, ahől a készítmény a) valamely zöld pőrfirin dózisegységéttartalmazza az érlerakódás kifejlődésének gátlására vagy megelőzésérealkalmas hatásős mennyiségben, ahől e dózist szándékős fénybesűgárzásmellőzésével adják be, b) és gyógyászatilag megfelelő segéd- ésvivőanyagőkat tartalmaz. A találmány szerinti zöld pőrfirintartalmúkészítmények hatásősan gátőlják az artéria falán keletkezőzsírlerakódásők, főltők képződését az esetben is, ha a kezelésnél nemalkalmaznak szándékősan fénybesűgárzást. ŕ
HU0001063A 1996-06-14 1997-06-05 Use of green porphyrins in the manufacture of a medicament treating atherosclerosis HUP0001063A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/663,890 US5834503A (en) 1996-06-14 1996-06-14 Methods to treat arterial plaque
PCT/CA1997/000393 WO1997048393A1 (en) 1996-06-14 1997-06-05 Use of green porphyrins in the manufacture of a medicament in the treatment of atherosclerosis without purposeful irradiation of the porphyrin derivatives

Publications (2)

Publication Number Publication Date
HUP0001063A2 true HUP0001063A2 (hu) 2000-09-28
HUP0001063A3 HUP0001063A3 (en) 2001-02-28

Family

ID=24663656

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0001063A HUP0001063A3 (en) 1996-06-14 1997-06-05 Use of green porphyrins in the manufacture of a medicament treating atherosclerosis

Country Status (13)

Country Link
US (2) US5834503A (hu)
EP (1) EP0910371A1 (hu)
JP (1) JP2000512300A (hu)
KR (1) KR20000016656A (hu)
CN (1) CN1101188C (hu)
AR (1) AR008392A1 (hu)
AU (1) AU714045B2 (hu)
CA (1) CA2257564A1 (hu)
HU (1) HUP0001063A3 (hu)
NO (1) NO985829L (hu)
NZ (1) NZ333236A (hu)
TW (1) TW514527B (hu)
WO (1) WO1997048393A1 (hu)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834503A (en) * 1996-06-14 1998-11-10 Qlt Phototherapeutics, Inc. Methods to treat arterial plaque
DE19824653A1 (de) * 1998-02-25 1999-08-26 Schering Ag Nekrose-affine Verbindungen und ihre Verwendung zur Herstellung von Präparaten zur Pharmakotherapie
US6331235B1 (en) * 1998-12-11 2001-12-18 The University Of British Columbia Chiral separation of benzoporphyrin derivative mono-and di-acids by laser-induced fluorescence capillary electrophoresis
US6609014B1 (en) * 1999-04-14 2003-08-19 Qlt Inc. Use of PDT to inhibit intimal hyperplasia
US7022843B1 (en) 1999-04-14 2006-04-04 The University Of British Columbia β,β′-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
US20040229295A1 (en) * 1999-05-17 2004-11-18 Marchitto Kevin S. Activated delivery of biomolecules using electromagnetic energy
US20040208855A1 (en) * 1999-11-17 2004-10-21 Allison Beth Anne Use of PDT to inhibit intimal hyperplasia
US6750037B2 (en) 1999-12-27 2004-06-15 Edwin L. Adair Method of cancer screening primarily utilizing non-invasive cell collection, fluorescence detection techniques, and radio tracing detection techniques
US6984498B2 (en) * 1999-12-27 2006-01-10 Adair Edwin L Method of cancer screening primarily utilizing non-invasive cell collection, fluorescence detection techniques, and radio tracing detection techniques
AU2002233092A1 (en) 2001-02-15 2002-08-28 Qlt Inc. Reduction or prevention of pdt related inflammation
US6790463B2 (en) * 2001-03-30 2004-09-14 Robert F. Hofmann Uses of targeted oxidative therapeutic formulation in arteriosclerosis
US20030103995A1 (en) * 2001-06-04 2003-06-05 Hamblin Michael R. Detection and therapy of vulnerable plaque with photodynamic compounds
EP1374912B1 (en) * 2002-06-21 2006-08-16 Edwin L. Adair Use of metaloporphyrins for treatment of arteriosclerotic lesions
US20080260650A1 (en) * 2004-10-28 2008-10-23 The General Hospital Corporation Methods of Detection and Therapy of Inflamed Tissues Using Immune Modulation
WO2006049599A1 (en) * 2004-10-28 2006-05-11 The General Hospital Corporation Methods of detection and therapy for atheromatous plaques using immune modulation
US8109981B2 (en) 2005-01-25 2012-02-07 Valam Corporation Optical therapies and devices
US20070299431A1 (en) * 2006-05-02 2007-12-27 Green Medical, Inc. Systems and methods for treating superficial venous malformations like spider veins
US7465312B2 (en) 2006-05-02 2008-12-16 Green Medical, Inc. Systems and methods for treating superficial venous malformations like spider veins
PE20110591A1 (es) 2008-07-28 2011-09-15 Takeda Pharmaceutical Composicion farmaceutica estabilizada a base de un compuesto no peptidico
US7968127B2 (en) * 2008-07-28 2011-06-28 Winslow David E Reverse vitamin K effect via photodynamic oxidation targeted at vascular endothelium, fibrin and blood platelets
CN115054703B (zh) * 2022-06-30 2023-08-04 东南大学 具有近红外光响应性和靶向性的脂质体、制备方法及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4577636A (en) * 1982-11-23 1986-03-25 The Beth Israel Hospital Association Method for diagnosis of atherosclerosis
US4512762A (en) * 1982-11-23 1985-04-23 The Beth Israel Hospital Association Method of treatment of atherosclerosis and a balloon catheter for same
US5171749A (en) * 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
US5095030A (en) * 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US4920143A (en) * 1987-04-23 1990-04-24 University Of British Columbia Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
US5283255A (en) * 1987-01-20 1994-02-01 The University Of British Columbia Wavelength-specific cytotoxic agents
US5129396A (en) * 1988-11-10 1992-07-14 Arye Rosen Microwave aided balloon angioplasty with lumen measurement
US5214036A (en) 1990-03-08 1993-05-25 University Of British Columbia Benzoporphyrin derivatives for photodynamic therapy
US5053423A (en) * 1990-03-22 1991-10-01 Quadra Logic Technologies Inc. Compositions for photodynamic therapy
EP0650368A1 (en) * 1992-06-24 1995-05-03 Cortex Pharmaceuticals, Inc. Use of calpain inhibitors in the inhibition and treatment of medical conditions associated with increased calpain activity
US5422362A (en) * 1993-07-29 1995-06-06 Quadra Logic Technologies, Inc. Method to inhibit restenosis
DE69434598T3 (de) * 1993-07-29 2010-07-29 The United States Of America Represented By The Secretary, Department Of Health And Human Services Verwendung von Paclitaxel und seinen Derivaten zur Herstellung eines Medikaments für die Behandlung von Restenose
US5789433A (en) * 1995-01-17 1998-08-04 Quadra Logic Technologies, Inc. Green porphyrins as immunomodulators
US5834503A (en) * 1996-06-14 1998-11-10 Qlt Phototherapeutics, Inc. Methods to treat arterial plaque

Also Published As

Publication number Publication date
AU714045B2 (en) 1999-12-16
CN1222076A (zh) 1999-07-07
NO985829L (no) 1999-02-11
EP0910371A1 (en) 1999-04-28
AR008392A1 (es) 2000-01-19
US5834503A (en) 1998-11-10
CN1101188C (zh) 2003-02-12
AU2947097A (en) 1998-01-07
NO985829D0 (hu) 1998-12-11
JP2000512300A (ja) 2000-09-19
KR20000016656A (ko) 2000-03-25
NZ333236A (en) 2000-06-23
HUP0001063A3 (en) 2001-02-28
TW514527B (en) 2002-12-21
US6235767B1 (en) 2001-05-22
CA2257564A1 (en) 1997-12-24
WO1997048393A1 (en) 1997-12-24

Similar Documents

Publication Publication Date Title
HUP0001063A2 (hu) Zöld porfirinek alkalmazása ateroszklerózis kezelésére szolgáló gyógyászati készítmények előállítására
NO20014842D0 (no) Docetaksel i kombinasjon med rhuMAb HER2 for behandling av kreft
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
ATE319447T1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
NO931267L (no) Fremgangsmaate for behandling eller forebyggelse av type 1diabetes ved oral administrering av insulin
PT913156E (pt) Utilizacao de proteina c activada para tratar estados hipercoagulaveis associados com sepsia
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
BR0113447A (pt) Método de tratamento ou prevenção do câncer em um ser humano, e, composição farmacêutica
FI922325A0 (fi) Oral sammansaettning foer botning av inflammatoriska tarmkanalsjukdomar.
MX9302038A (es) Metodo para el tratamiento del cancer por una terapia conjunta con derivados de 2-halometilideno y un agente antineoplasico especifico de fase m o fase s.
EA199900499A1 (ru) Фармацевтическая композиция, включающая соединение, обладающее анти-xa активностью, и соединение антагонист агрегации тромбоцитов
DE69426334D1 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
DK47089D0 (da) Middel med oedelaeggende virkning paa maligne tumorer, fremgangsmaade til fremstilling af saadanne midler og anvendelse af disse til terapeutisk behandling af cancer
EA200000176A1 (ru) Применение физиологически приемлемых соединений, солей и комплексов ванадия
KR970061244A (ko) 치매 치료용 약학 조성물
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
CZ20011550A3 (cs) Opticky aktivní derivát pyridyl-4H-1,2,4-oxadiazinu, jeho použití při léčbě vaskulárních onemocnění a farmaceutické kompozice ho obsahující
KR970704442A (ko) 일시적인 병소 허혈에 의해 유발된 재관류 손상을 치료하기 위한 (S)-아데노실-L-메티오닌(SAMe) 및 그의 생리학상 적합한 염의 용도(Use of (S)-Adenosy-L-Methionine(SAMe) and lts Physiologically Compatible Salts for Treating Reperfusion Damage Triggered by Temporary Focal lschaemia)
WO1997026880A3 (en) Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients
DK0593562T3 (da) Topisk præparat indeholdende penciclovir
NO984196L (no) FremgangsmÕte for behandling av stoffmisbruk
Cutler et al. Tolerability profiles of AChEIs: a critical component of care for Alzheimer's disease patients
ATE107504T1 (de) Arzneimittel zur behandlung von kryptosporidiose.
TR200200111T2 (tr) Neoplazmalar için terapötik ve profilaktik maddeler
Fann et al. Halazepam in the treatment of recurrent anxiety attacks in chronically anxious outpatients: A double-blind placebo controlled study.